Priyangu phanta and priyangu taila uttara basti in the management of asrigdara ( dysfuctional uterine bleeding)
- Conditions
- Diseases of the genitourinary system. Ayurveda Condition: ASRUGDARAH/RAKTAPRADARAH,
- Registration Number
- CTRI/2022/04/042269
- Lead Sponsor
- Faculty of Ayurveda Institue of Medical Sciences Banaras Hindu University
- Brief Summary
In today scenario disorder of menstruation is the commonest amongst all the gynecological complaints, which have a direct effect on the physical as well as physiological health of the female ,,Asrigdara is a disease in which excessive and prolonged blood loss during menstruation or even blood loss during intermenstrual period along with different form of normal menstrual blood. Excessive and prolonged bleeding may cause Angmarda (body ache), Dourbalaya (weakness), Daha (burning sensation), Trisha (thirst), Bharama (giddiness), Pralapa (delirium), Panduta (anaemia),Oral use of priyangu Phanta and Uttarabasti with Priyangu taila are one of them which are specific treatment in gynecological and menstrual disorders, All the registered patients will be divided randomly in 3 trial groups ,Group A will be treated with oral administration of Priyangu Phanta (40ml) for duration of 90 days,Group B will be treated with intrauterine instillation of Priyangu Taila (5-15 ml) by Uttara Basti up to 3 days continuously followed by gap of next 3dyas and again administration for next consecutive 3days,Before Uttara Basti, Asthapana Basti will be given for 2days, Group C will be treated with both oral administration of Priyangu Phanta (40ml) for duration of 90 days and Intrauterine instillation of Priyangu Taila (5-15 ml) by Uttara Basti up to 3 days continuously followed by gap of next 3dyas and again administration for next consecutive 3days,Before Uttara Basti, Asthapana Basti will be given for 2days,Total four (4) follow ups will be done at regular interval of one month or as per duration & interval of her menstrual cycle for 4 consecutive cycles,T hree (3) follow ups will be done with medication and one (1) without medication to see the changes in parameters, assessment will be done on the basis of prepared propforma or subjective and objective parameters including improvement in sign and symptoms of Asrigdara
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Female
- Target Recruitment
- 60
Patients willing to participate in the research work after giving well informed written consent, Women between age group 18 to 45 years (all nulliparous and multiparous women) having all or any signs & symptoms of Asrigdara as Excessive bleeding, Prolonged duration, Intermenstrual bleeding, Other than characteristics of menstrual blood.
Age below 18 and above 45 years,Bleeding followed by abortion,Bleeding from the site other than the uterus,Any abnormalities detected in investigation ( routine and specific), Coagulation disorders, Patient suffering from chronic systemic diseases like uncontrolled hypertension, uncontrolled diabetes, venereal disease, Thyroid dysfunction, renal diseases, jaundice or any disorders influencing general physical health and ultimately influencing menses, Patient using IUCD & OCPs or injectable contraceptives & others, any history of allergy or allergy from trial, Central nervous system disorders like epilepsy, meningitis, migraine or any other psychological, Respiratory disorders like bronchial asthma, tuberculosis, pneumonia, pleural effusion, bronchitis, Cardiac disorders like angina, myocardial infarction, congenital anomaly of heart, Gastrointestinal disorders like appendicitis, cholecystitis, hepatitis, pancreatitis, cholelithiasis, diverticulitis, gastric ulcer, irritable bowel syndrome & others,organic pelvic pathology, benign and malignant tumors(Vulval, vaginal, rectal, cervical, uterine), PID, congenital anomalies of genital tract and different type of infections of genital, breast carcinoma, Patient is on chemotherapy/ radiotherapy for any malignant condition of any organ.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment will be done on the basis of prepared proforma and improvement in sign and symptoms of asrigdara 90 days 1Average Amount of menstrual blood loss 90 days 2 Normal Duration of menstrual blood loss 90 days 3 Normal Colour of menstrual blood loss 90 days 4 Normal Consistency of menstrual blood loss 90 days 5 Relief in Pain in abdomen during menses 90 days 6 Relief in Associated symptoms 90 days 7 Normal Endometrial thickness 90 days 8 Normal Serum Estradiol 90 days
- Secondary Outcome Measures
Name Time Method Improvement in criteria listed in different scales Total four (4) follow-ups will be done at regular interval of one month or as
Trial Locations
- Locations (1)
SSH Banaras Hindu University
🇮🇳Varanasi, UTTAR PRADESH, India
SSH Banaras Hindu University🇮🇳Varanasi, UTTAR PRADESH, IndiaDR Sunita SumanPrincipal investigator7607165096ssom18@gmail.com